JANX Janux Therapeutics
- 50.310
- +3.810+8.19%
- 50.750
- +0.440+0.87%
Janux Therapeutics News
Janux Therapeutics Initiated at Outperform by Leerink Partners
Leerink Partners Initiates Janux Therapeutics(JANX.US) With Buy Rating, Announces Target Price $79
Stifel Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $70
Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX), 89bio (ETNB) and Ardent Health Partners, Inc. (ARDT)
Janux Therapeutics Analyst Ratings
Stifel Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $70
Cantor Fitzgerald Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $100
TD Cowen Maintains Janux Therapeutics(JANX.US) With Buy Rating
Janux Therapeutics Inc (JANX) Receives a Buy From Cantor Fitzgerald
Analysts' Opinions Are Mixed on These Healthcare Stocks: CVS Health (CVS), Amicus (FOLD) and Janux Therapeutics Inc (JANX)
H.C. Wainwright Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $63
Buy Rating for Janux Therapeutics Driven by Promising Pipeline and Strong Financial Position
BTIG Maintains Janux Therapeutics(JANX.US) With Buy Rating, Raises Target Price to $82
TD Cowen Maintains Janux Therapeutics(JANX.US) With Buy Rating
JonesTrading Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $70
Janux Therapeutics Analyst Ratings
UBS Initiates Janux Therapeutics(JANX.US) With Buy Rating, Announces Target Price $69
Janux Therapeutics Initiated With a Buy at UBS
Janux Therapeutics Price Target Maintained With a $100.00/Share by Cantor Fitzgerald
Janux Therapeutics Analyst Ratings
Analysis
Price Target
No Data
No Data